> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/author_index/frequency_index.md). # FREQUENCY\_INDEX The Frequency Index organizes the BREXAtlas Encyclopedia according to reported frequencies, electromagnetic exposure ranges, and signal architectures observed across the 44 foundational studies. The purpose of this index is to identify recurring frequency-response relationships and support future development of a Frequency Specificity Atlas. ## 50 kHz **Primary Context** Low-frequency comparison exposures. **Supporting BRE Entries** * BRE-042 **Tissue Types** * Glioblastoma **Why It Matters** Used as a comparison frequency in tumor-network studies. ## 100–150 kHz **Primary Context** TTFields frequency range observed across multiple cancers. **Supporting BRE Entries** * BRE-002 * BRE-021 * BRE-037 * BRE-039 * BRE-040 **Tissue Types** * Glioblastoma * Breast Cancer * Melanoma * Mesothelioma * Lung Cancer * Liposarcoma **Why It Matters** Represents one of the most frequently recurring TTFields frequency ranges. ## 150 kHz **Primary Context** Mesothelioma, Lung Cancer, Liposarcoma **Supporting BRE Entries** * BRE-037 * BRE-039 * BRE-040 **Cell Lines / Systems** * A549 * H460 * SW872 * 94T778 * STELLAR Trial Systems **Why It Matters** Appears repeatedly outside glioblastoma and may represent an important cross-cancer TTFields frequency. ## 200 kHz **Primary Context** Glioblastoma **Supporting BRE Entries** * BRE-001 * BRE-002 * BRE-014 * BRE-015 * BRE-016 * BRE-036 * BRE-042 **Cell Lines** * F-98 * U-87 * U-118 * S24 * BG5 * T269 **Why It Matters** The most consistently observed glioblastoma TTFields frequency. ## 100–300 kHz **Primary Context** General TTFields Operating Range **Supporting BRE Entries** * BRE-021 * BRE-036 **Why It Matters** Represents the broader TTFields optimization window reported across multiple studies. ## Radiofrequency (RF) Systems **Primary Context** Amplitude-Modulated Electromagnetic Therapy **Supporting BRE Entries** * BRE-030 * BRE-043 **Exposure Architecture** * 27.12 MHz carrier frequency * Tumor-specific modulation frequencies **Tissue Types** * Breast Cancer * Liver Cancer * Brain Metastasis Systems **Why It Matters** Represents a frequency platform fundamentally different from TTFields. ## Tumor-Specific Modulation Frequencies **Primary Context** Cancer-Specific Signal Targeting **Supporting BRE Entries** * BRE-002 * BRE-030 * BRE-043 **Related Discoveries** * DISC-001 * DISC-028 **Why It Matters** Supports the hypothesis that frequency response may be tissue-specific rather than universal. ## Electromagnetic Pattern Selectivity **Primary Context** Waveform and Modulation Architecture **Supporting BRE Entries** * BRE-030 * BRE-032 **What BREXAtlas Found** Signal architecture may matter as much as frequency. Observed variables include: * waveform structure * modulation pattern * timing * signal complexity **Why It Matters** Future bioelectric therapies may require optimization of more than frequency alone. ## Frequency Gaps The following frequency questions remain unresolved: * **FG-001** — What is the optimal frequency for each cancer type? * **FG-002** — Can a universal anticancer frequency exist? * **FG-003** — Do neighboring frequencies produce similar responses? * **FG-004** — How do intensity and frequency interact? * **FG-005** — How does frequency interact with calcium signaling? * **FG-006** — How does frequency interact with tumor networks? * **FG-007** — Can a complete cancer-frequency atlas be constructed? ## Frequency Summary The strongest recurring finding in Volume I is that frequency appears to matter. Evidence from TTFields, RF oncology, calcium-channel studies, and clinical systems repeatedly suggests that biological response is influenced not only by exposure, but by the specific frequency architecture used. The long-term goal of BREXAtlas is to build a comprehensive Frequency Specificity Atlas linking: * frequency * tissue * cell line * mechanism * discovery * response into a predictive bioelectric oncology framework. --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://www.brexatlas.org/author_index/frequency_index.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.